How many insider trades does FilingIQ track for CDXS?

FilingIQ tracks 486 Form 4 insider transactions for CDXS (CODEXIS, INC.), covering filings from Nov 10, 2014 onwards. 4 of those were filed in the last 90 days.

Are CDXS insiders net buyers or net sellers?

Across the full Form 4 history for CDXS, 58 transactions (12%) were open-market purchases and 211 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CDXS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CDXS in?

CODEXIS, INC. (CDXS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $105.68M.

CDXS insider trading

NasdaqGS Healthcare

CODEXIS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

486

Last 90 days

Buys / sells

12% / 43%

Market cap

$105.68M

About CODEXIS, INC.

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Company website: www.codexis.com

CDXS insider activity at a glance

FilingIQ has scored 486 insider transactions for CDXS since Nov 10, 2014. The most recent filing in our index is dated Feb 24, 2026.

Across the full history, 58 open-market purchases and 211 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CDXS insider trades is 49.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CDXS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding CDXS

Opaleye Management Inc.

$11.07M · 1.5% of AUM

Casdin Capital, LLC

$6.20M · 0.5% of AUM

Frequently asked

How many insider trades does FilingIQ track for CDXS?: FilingIQ tracks 486 Form 4 insider transactions for CDXS (CODEXIS, INC.), covering filings from Nov 10, 2014 onwards. 4 of those were filed in the last 90 days.
Are CDXS insiders net buyers or net sellers?: Across the full Form 4 history for CDXS, 58 transactions (12%) were open-market purchases and 211 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CDXS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CDXS in?: CODEXIS, INC. (CDXS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $105.68M.

Methodology & sources

Every CDXS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.